Swipe om te navigeren naar een ander artikel
The objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.
This study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.
Within each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.
Results suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D’s limited response options relative to mild disease.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
The EuroQoL Group. (1990). EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam), 16, 199–208. doi: 10.1016/0168-8510(90)90421-9.
WHO Strategy for prevention and control of Chronic Respiratory Diseases. www.who.int.
Global initiative for asthma (GINA) guidelines. (1998). Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report.
Ståhl, E., Lindberg, A., Rönmark, E., Svensson, K., Jansson, S.-A., Andersson, F., et al. (2001). The level of health-related quality of life in patients with COPD and its dependence on age, gender, and disease severity. The European Respiratory Journal, 18(Suppl 33), 184s. doi: 10.1183/09031936.01.00084401.
Pauwels, R. A., Buist, A. S., Calverley, P. M., Jenkins, C. R., Hurd, S. S., & The GOLD Scientific Committee. (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine, 163(5), 1047–1048.
Szende, A., Oppe, M., & Devlin, N. (Eds.), (2007). The European VAS value set. In EQ–5D value sets. Inventory, comparative review and user guide (pp. 83–85). Dordrecht: Springer.
Dolan, P., & Sutton, M. (1997). Mapping VAS scores onto TTO and SG utilities. Social Science and Medicine, 44, 1289–1297. doi: 10.1016/S0277-9536(96)00271-7.
Konig, H. H., Ulshofer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., et al. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 14(11), 1205–1215. doi: 10.1097/00042737-200211000-00008. PubMedCrossRef
Wu, A. W., Jacobson, K. L., Frick, K. D., Clark, R., Revicki, D. A., Freedberg, K. A., et al. (2002). Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Quality of Life Research, 11(3), 273–282. doi: 10.1023/A:1015240103565. PubMedCrossRef
Sach, T. H., Barton, G. R., Doherty, M., Muir, K. R., Jenkinson, C., & Avery, A. J. (2007). The relationship between body mass index and health-related quality of life: Comparing the EQ-5D, EuroQol VAS and SF-6D. International Journal of Obesity (London), 31(1), 189–196. doi: 10.1038/sj.ijo.0803365. CrossRef
Barton, G. R., Sach, T. H., Doherty, M., Avery, A.J., Jenkinson, C., & Muir K. R. (2007). An assessment of the discriminative ability of the EQ-5D (index), SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. The European Journal of Health Economics Jun 29 [Epub ahead of print].
Franks, P., Hanmer, J., & Fryback, D. G. (2006). Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample toward consistency in cost-effectiveness analyses. Medical Care, 44(5), 478–485. doi: 10.1097/01.mlr.0000207464.61661.05. PubMedCrossRef
Boonen, A., van der Heijde, D., Landewe, R., van Tubergen, A., Mielants, H., Dougados, M., et al. (2007). How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Annals of the Rheumatic Diseases, 66(6), 771–777. doi: 10.1136/ard.2006.060384. PubMedCrossRef
Grieve, R., Grishchenko, M., & Cairns, J. (2008). SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. The European Journal of Health Economics. (Epub ahead of print).
- Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D
N. K. Leidy
- Springer Netherlands